Working… Menu

Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03943043
Recruitment Status : Recruiting
First Posted : May 9, 2019
Last Update Posted : May 9, 2019
Information provided by (Responsible Party):
Istituto Clinico Humanitas

Brief Summary:

The objective of the study is to determine a new combination of drug that improves the outcome in patients with advanced (unresectable or metastatic) BTC. The primary objective of the phase I part of the study is to determine the maximum tolerated dose (MTD) of the combination gemcitabine plus oxaliplatin plus nab-paclitaxel, established in the first cycle of therapy, in order to determine the recommended phase II dose (RP2D).

The primary objective of the phase II is to determine activity of GEMOX plus nab-paclitaxel. The secondary objectives of the study consist in to better define the safety profile and the outcome of the study treated population.

Condition or disease Intervention/treatment Phase
Cholangiocarcinoma Drug: nab-paclitaxel Phase 1 Phase 2

Detailed Description:

Systemic chemotherapy is increasingly being applied in cases of biliary tract cancers. A benefit for chemotherapy over best supportive care alone was suggested in a trial that randomly assigned 90 patients with advanced pancreatic or biliary cancer (37 with bile duct cancer) to fluorouracil (FU)-based systemic chemotherapy or best supportive care alone (median survival 6 versus 2.5 months, respectively) (1).

The literature regarding treatment results with specific regimens is limited because most series are small, and many reports consist of a mix of bile duct cancers, gallbladder cancer, ampullary cancer, and either pancreatic or hepatocellular cancers. Although they arise in similar locations, these cancers all have a unique natural history and response to chemotherapy. In general, no single drug or combination has consistently increased median survival beyond the expected six to eight months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 85 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Phase I-II Trial of Gemcitabine Plus Oxaliplatin and Nab-paclitaxel in Subjects With Advanced (Unresectable or Metastatic) Biliary Tract Cancer
Actual Study Start Date : July 21, 2017
Estimated Primary Completion Date : May 1, 2020
Estimated Study Completion Date : May 1, 2021

Arm Intervention/treatment
Experimental: gemcitabine oxaliplatin nab-paclitaxel
combination at different dose of gemcitabine, oxaliplatin and nab-paclitaxel
Drug: nab-paclitaxel

Phase I dosing regimens:

The dose of treatment will be assigned at the time of enrolment in one of these 3 subsequent dose-levels:

- 1° level: gemcitabine 800 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 80 mg/m2 0° level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 100 mg/m2

  1. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 125 mg/m2
  2. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 150 mg/m2 each administered on day 1, every 14 day

Phase II:

Gemcitabine plus oxaliplatin plus nab-paclitaxel according to RP2D.

Other Names:
  • Gemcitabine
  • Oxaliplatin

Primary Outcome Measures :
  1. maximum tolerated dose [ Time Frame: 4 weeks ]
    Determination of the maximum tolerated dose for phase I

Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 16 weeks ]
    The secondary objectives of the study consist in to better define the safety profile as assessed by CTCAE V4.0

  2. Number of responder (in term of CR, PR, SD) to GEMOX plus nab-paclitaxel as assessed by RECIST 1.1 [ Time Frame: Maximum of 24 weeks ]
    Determination of activity of GEMOX plus nab-paclitaxel as assessed by RECIST 1.1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written, signed informed consent
  • Male or female aged 18 years or older
  • Histologically or citologically-confirmed advanced (unresectable or metastatic) BTC (gallbladder cancer, cancer of the extrahepatic bile duct, intrahepatic cholangiocarcinoma and ampullary carcinoma)
  • Measurable or evaluable but non-measurable disease according to RECIST v. 1.1
  • Chemotherapy-naïve (prior chemotherapy in the adjuvant setting completed more than 6 months before the trial entry is accepted)
  • Adequate bone marrow, liver, and renal function
  • ECOG PS 0-1
  • Life expectancy of at least 12 weeks
  • Negative serum pregnancy test for women of childbearing potential;
  • Adoption of adequate contraceptive methods when applicable Women of child-bearing potential must use the following adequate contraceptive methods during all the study and for 1 month after completion of study treatment: abstinence, tubal ligation, oral contraception or transdermal contraceptives, copper intrauterine device, vasectomy of the partner. For male patients with female partners of childbearing potential, agreement to use a barrier method of contraception from the first dose of treatment and for 6 months after completion of study treatment.
  • Male patients mustn't donate sperm during the treatment with nab-paclitexel and for 6 months after completion of study treatment.
  • Agreement not to donate blood during the study.

Exclusion Criteria:

  • Peripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 4.0. In CTCAE version 4.0 grade 2 sensory neuropathy is defined as moderate symptoms; limiting instrumental activities of daily living (ADLs)
  • Previous systemic treatment for advanced disease
  • Known symptomatic brain metastases or carcinomatous meningitis
  • Severe or uncontrolled systemic disease and/or active or uncontrolled infection
  • Women who are currently pregnant or breast feeding
  • Previous or current malignancies of other histologies within the last 3 years, with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin
  • Known hypersensitivity to nab-paclitaxel, gemcitabine, oxaliplatin or any of the excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03943043

Layout table for location contacts
Contact: Armando Santoro, MD 02 82244080
Contact: Tiziana Pressiani, MD 02 82244773

Layout table for location information
Istituto Clinico Humanitas Recruiting
Rozzano, Milan, Italy, 20089
Contact: Armando Santoro, MD    02 82244080   
Sponsors and Collaborators
Istituto Clinico Humanitas
Layout table for investigator information
Principal Investigator: Armando Santoro, MD Istituto Clinico Humanitas

Layout table for additonal information
Responsible Party: Istituto Clinico Humanitas Identifier: NCT03943043     History of Changes
Other Study ID Numbers: ONC-2016-001
2016-004118-84 ( EudraCT Number )
First Posted: May 9, 2019    Key Record Dates
Last Update Posted: May 9, 2019
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Biliary Tract Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Biliary Tract Diseases
Digestive System Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs